4 completed, 2 not yet recruiting, 1 active not recruiting. 3 Phase 2, 2 Not applicable.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 3 | Completed 2, Active not recruiting 1 |
| Not applicable | 2 | Completed 1, Not yet recruiting 1 |
Follow Normal Tension Glaucoma (NTG): new trials by email Literature Review of Normal Tension Glaucoma (NTG) trials Research Report on Normal Tension Glaucoma (NTG)
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Single-site Pilot Study Evaluating the Effect of QLS-111 Ophthalmic Solution on Posterior Perfusion and Vessel Dilation QLS-111 Ophthalmic Solution (0.015%), QLS-111 Ophthalmic Solution (0.075%) - Non-proliferative Diabetic Retinopathy (NPDR), Open-angle Glaucoma (OAG) | Phase 2 | Active not recruiting | Qlaris Bio, Inc. | 14 | 2026-02-20 | 2026-09-14 |
| DSLT in Normal Tension Glaucoma (NTG) Asian Eyes Direct Selective Laser Trabeculoplasty (DSLT) - Normal Tension Glaucoma (NTG), Glaucoma | Not applicable | Not yet recruiting | Ngoc Nguyen Inc. | 40 | 2026-01-01 | 2025-12-24 |
| Optic Nerve Head Evaluation Through Multimodal Blood Flow Analysis: a Prospective Observational, Multi-center Study Neuro-Ophthalmology, Optic Neuropathies | Not yet recruiting | Barboni | 70 | 2025-10-01 | 2025-07-20 | |
| Study of an Investigational Product, QLS-111, Provided as an Eyedrop, for Treatment of Normal Tension Glaucoma (NTG) QLS-111 ophthalmic solution (0.015%), Timolol Maleate PF 0.5% Ophthalmic Solution (Timolol) - Normal Tension Glaucoma (NTG), Low-Tension Glaucoma, Bilateral | Phase 2 | Completed | Qlaris Bio, Inc. | 37 | 2025-08-13 | 2026-04-03 |
| 24-hour Wear Performance and Safety Study of Smartlens miLens Contact Lens for IOP Monitoring miLens system - Glaucoma, GLAUCOMA 1, OPEN ANGLE, D (Disorder) | Completed | Smartlens, Inc. | 86 | 2025-02-19 | 2026-04-01 | |
| Trabecular Microbypass IStent in Patients with Glaucoma first generation iStent (Glaukos, San Clemente, CA, USA) insertion, phacoemulsification - Primary Open Angle Glaucoma (POAG), Istent Inject W | Not applicable | Completed | Yu-Ting Tsao | 71 | 2022-05-16 | 2024-10-08 |
| A Study to Evaluate Safety and Tolerability of QLS-101 in NTG QLS-101, Timolol maleate PF 0.5% ophthalmic solution - Normal Tension Glaucoma (NTG) | Phase 2 | Completed | Qlaris Bio, Inc. | 30 | 2021-09-15 | 2025-01-20 |
Low Tension Glaucoma (7) · Glaucoma (5) · Glaucoma, Open-Angle (4) · Diabetic Retinopathy (1) · Ocular Hypertension (1) · Optic Atrophy, Hereditary, Leber (1) · Optic Disk Drusen (1) · Optic Nerve Diseases (1) · Optic Neuropathy, Ischemic (1)
Eye Diseases (7) · Ocular Hypertension (6) · Optic Nerve Diseases (6) · Cardiovascular Diseases (2) · Glaucoma (2) · Vascular Diseases (2) · Congenital, Hereditary, and Neonatal Diseases and Abnormalities (1) · Cranial Nerve Diseases (1) · Diabetes Complications (1) · Diabetes Mellitus (1) · Diabetic Angiopathies (1) · Endocrine System Diseases (1) · Eye Diseases, Hereditary (1) · Genetic Diseases, Inborn (1) · Heredodegenerative Disorders, Nervous System (1)
Ophthalmic Solutions (2) · Timolol (2) · Mutagenesis, Insertional (1) · Phacoemulsification (1)
Qlaris Bio, Inc. (3) · Barboni (1) · Ngoc Nguyen Inc. (1) · Smartlens, Inc. (1) · Yu-Ting Tsao (1)
United States (4) · South Korea (1) · Taiwan (1)
B. Wirostko, M.D. (1) · Barbara M Wirostko, MD (1) · Lisa Brandano (1)